• Support
  • Contact Us
  • Corporate website
  • Customer Care
  • Training

  • ScienceWatch Home
  • Inside This Month...
  • Interviews

Featured Interviews
Author Commentaries
Institutional Interviews
Journal Interviews
Podcasts

  • Analyses

Featured Analyses
What's Hot In...
Special Topics

  • Data & Rankings

Sci-Bytes
Fast Breaking Papers
New Hot Papers
Emerging Research Fronts
Fast Moving Fronts
Corporate Research Fronts
Research Front Maps
Current Classics
Top Topics
Rising Stars
New Entrants
Country Profiles

  • About Science Watch

Methodology
Archives
Contact Us
RSS Feeds

 ScienceWatch

2009 : November 2009 - New Hot Papers : Bob Freedman on Nicotinic Agonist in Schizophrenia

NEW HOT PAPERS - 2009

November 2009 Download this article
 
Robert Freedman talks with ScienceWatch.com and answers a few questions about this month's New Hot Paper in the field of Psychiatry/Psychology.
Robert Freedman Article Title: Initial phase 2 trial of a nicotinic agonist in schizophrenia
Authors: Freedman, R;Olincy, A;Buchanan, RW;Harris, JG;Gold, JM;Johnson, L;Allensworth, D;Guzman-Bonilla, A;Clement, B;Ball, MP;Kutnick, J;Pender, V;Martin, LF;Stevens, KE;Wagner, BD;Zerbe, GO;Soti, F;Kem, WR
Journal: AMER J PSYCHIAT
Volume: 165, Issue: 8, Page: 1040-1047, Year: AUG 2008
* Univ Colorado, Hlth Sci Ctr, Dept Psychiat C249 32, Denver, CO 80262 USA.
* Denver VA Med Ctr, Dept Psychiat, Denver, CO USA.
(addresses have been truncated)

 Why do you think your paper is highly cited?

The targeting of nicotinic receptors for therapeutic treatment of mental disorders is an emerging field of translational research. A long history of basic inquiry into this mechanism of neurotransmission is now being used to devise new treatment possibilities for patients.

 Where do you see your research leading in the future?

The future of psychiatric treatment involves translating basic research in neurobiology into new therapeutic strategies. As Editor of the American Journal of Psychiatry, where this paper was published, I believe that journals should disseminate the results of early therapeutic investigations to encourage other investigators to undertake similar translational studies.

Robert Freedman, M.D.
Professor and Chair
Department of Psychiatry
University of Colorado
Denver, Colorado, USA
Web | Web | Web

KEYWORDS: CONSENSUS COGNITIVE BATTERY; ALPHA-BUNGAROTOXIN; NEGATIVE SYMPTOMS; DOUBLE-BLIND; CLOZAPINE; RECEPTORS; RELIABILITY; SMOKING; DEFICIT; GTS-21.

Download this article

back to top


2009 : November 2009 - New Hot Papers : Bob Freedman on Nicotinic Agonist in Schizophrenia

  • © 2020 Clarivate
  • Careers
  • Copyright
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
Follow us Share to Twitter Share to LinkedIn Share to Facebook Share to Instagram
Previous
left arrow key
Next
right arrow key
Close Move